Santa Ana, CA, September 25, 2017 – After a three-day trial, a jury entered a unanimous verdict in favor of Plaintiff Imagenetix, Inc., finding that Defendant Robinson Pharma, Inc. and related entities willfully induced infringement of Patent No. 5,569,676, which was owned by Imagenetix. The jury awarded damages in the amount of $6,832,842. Based on the jury’s willfulness finding, Imagenetix plans to seek enhanced damages and attorneys’ fees.
Imagenetix’s patent related to the use of cetyl myristoleate in the treatment of osteoarthritis. Defendants marketed products containing cetyl myristoleate for the treatment of osteoarthritis, Arthro-7 and Arthro-8, and explicitly cited Imagenetix’s patent in its marketing materials. Imagnenetix had offered to license the patent, and Defendants had negotiated to purchase the patent, but Defendants never purchased or licensed the patent despite continuing their sales and marketing efforts.
